Sermorelin Dosage in the Research Literature

The short version

This page reports the sermorelin dosage figures that appear in the published research — not instructions. In studies, sermorelin was given mostly by subcutaneous injection (under the skin), sometimes intravenously for testing. Children in the approved pediatric studies received about 30 mcg/kg once daily; aging-research participants received 0.5-1 mg twice daily. The peptide clears the blood fast (a roughly 10-12 minute half-life) yet still lifts growth hormone for about three hours. Everything below describes what researchers administered to study populations, framed as "studied at X in [population]" — never as a dose for any person to take.

Sermorelin Dosage in the Research Literature

Across the published record, sermorelin dosage is best read by study population and route, in research framing only [studied-at framing throughout].

Pediatric growth-hormone deficiency (efficacy study). A single daily subcutaneous dose of 30 mcg/kg at bedtime was used in the pediatric GHRH(1-29) efficacy program, accelerating first-year height velocity ^[1]. A separate long-term pediatric study used the same 30 mcg/kg once-daily subcutaneous dose for 12 to 24 months ^[8].

Aging research in older adults. Subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related GH and IGF-1 increases in older men ^[2]. A separate study of age-advanced men and women used a stabilized GHRH(1-29) analog at 10 mcg/kg nightly for 16 weeks ^[7].

Diagnostic and pharmacokinetic use. As a diagnostic GHRH-stimulation agent, a single intravenous bolus (commonly around 1 mcg/kg) was historically used to probe pituitary GH reserve. In a dedicated pharmacokinetic study, intravenous doses of 0.25-2 mcg/kg elicited GH release in healthy men, with maximal release at 1-2 mcg/kg ^[3].

None of these is a recommendation. They are the administered doses on record, reproduced so the literature can be read accurately. The full reported tolerability of these regimens is on the sermorelin side effects page.

Sermorelin half-life and why the route matters

Sermorelin's pharmacokinetics are defined by speed. After intravenous administration the native peptide is rapidly eliminated, with a plasma half-life on the order of 10-12 minutes — yet a single dose still elevates serum GH for roughly three hours ^[3]. The brief plasma residence and the longer downstream GH effect are not a contradiction; the pulse it triggers outlasts the molecule.

Route strongly shapes exposure. Subcutaneous injection is the primary route in the studies. Intravenous dosing was used for diagnostic and pharmacokinetic work. An intranasal route was examined historically but delivered only about 3-5% bioavailability ^[3] — a figure often cited to explain why oral, sublingual, and troche "sermorelin" formulations are widely criticized in research-user communities as ineffective, since peptides are degraded in the gut and poorly absorbed across mucosa. In normal men, a GHRH(1-29) analog stimulated GH dose-responsively across intravenous, subcutaneous, and intranasal routes, but required roughly a tenfold higher subcutaneous and thirtyfold higher intranasal dose relative to intravenous to do so ^[10].

That short native half-life is exactly what motivated longer-acting analogs — the engineering story told on the sermorelin vs CJC-1295 page.

Reconstitution, stability, and handling in research

Sermorelin acetate is supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions are prone to degradation. In research and compounding contexts it is reconstituted with a sterile diluent and, once reconstituted, typically refrigerated. Compounded preparations are prepared under USP <797> sterile-compounding standards.

These are handling and stability facts about the material as studied and compounded — not a protocol for use. This digest does not provide preparation, dosing, or administration instructions for any person; it reports what the literature and compounding standards describe about the substance itself.

How the studied doses fit together

Read as a whole, the dose record is coherent: small intravenous doses (sub-microgram to a few mcg/kg per kilogram) for acute testing, low once- or twice-daily subcutaneous milligram or microgram-per-kilogram doses for sustained axis stimulation, and bedtime timing where reinforcing the nocturnal GH pulse was the aim ^[14]. Long-term adult anti-aging dosing data, however, remain limited — the longest controlled adult tolerability windows here run roughly 14-16 weeks ^[7], with pediatric follow-up extending 12-24 months ^[8]. The numbers above describe study populations; they are not personal guidance, and decisions about any use belong to clinicians, not to a research digest.